Lantern Pharma Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors

Lantern Pharma Inc. (LTRN) presented Phase 1a clinical results for LP-184, a drug aimed at treating advanced solid tumors, particularly those deficient in DNA damage repair mechanisms. The company discussed the molecule's scientific background, clinical trial results, and implications for the treatment of DNA damage repair-deficient tumors. The webinar featured company participants, including CEO Panna Sharma, Chief Scientific Officer Kishor Bhatia, and Head of Clinical Development Reggie Ewesuedo, as well as collaborator Dr. Igor Astsaturov from Fox Chase.